Kechna Cadet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kechna Cadet has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Paige Brinzo
Schmidt College of Medicine Florida Atlantic University Boca Raton FL USA
2 shared publicationsSilvia S. Martins
Department of Emergency Medicine Columbia University Irving Medical Center New York NY USA
2 shared publicationsAmanda Hall
Dream.org, Oakland, CA, USA
1 shared publicationAmanda M. Bunting
Department of Population Health, New York University School of Medicine, USA
1 shared publicationAnnice Brown
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1 shared publication- Ashly E. Jordan
Center for Drug Use and HIV/HCV Research, New York, NY 10003, USA
1 shared publication
Latest Publications
- Open Access
- 17 November 2026
- Published by Springer Nature in Journal of Urban Health
The Neighborhood-Level Association Between Renter Cost Burden and Fatal Opioid-Involved Overdoses, Chicago, IL, 2015-2023
Housing insecurity, including homelessness and eviction, is linked to higher fatal overdose risk. However, the relationship between renter cost burden and fatal opioid-involved overdose remains unclear. This study examined the neighborhood-level association between renter cost burden and fatal opioid-involved overdoses across time in an urban setting. We conducted a cross-sectional analysis of Chicago census tracts using locations of opioid-involved fatal overdoses from the Cook County Medical Examiner’s Office, 2015–2023 ( n = 8423). Renter cost burden, defined as the percentage of renter households spending ≥ 30% of income on housing, was obtained for Chicago census tracts from the American Community Survey. We used negative binomial regression to estimate the association between renter cost burden and severe cost burden (≥ 50%) and fatal overdose rate by year, controlling for neighborhood variables (e.g., income, segregation, and population density). We observed positive spatial autocorrelation, indicating spatial clustering of census tracts with a high proportion of cost-burdened renters and fatal overdose rates. We found consistent positive associations between fatal overdose rates and renter cost burden and severe cost burden over time, controlling for neighborhood demographics. For example, in 2023, each 10-percentage point higher proportion of cost-burdened renters was associated with a 9% higher fatal overdose rate (aIRR = 1.09, 95% CI [1.02, 1.17]). These findings support further investigation of the relationship between renter cost burden and fatal overdose and motivate studies using quasi-experimental designs to assess whether upstream housing interventions (e.g., rental assistance) may reduce fatal overdose risk.
- 17 November 2026
- Published by Springer Nature in Journal of Urban Health
Open AccessThe Neighborhood-Level Association Between Renter Cost Burden and Fatal Opioid-Involved Overdoses, Chicago, IL, 2015-2023
Housing insecurity, including homelessness and eviction, is linked to higher fatal overdose risk. However, the relationship between renter cost burden and fatal opioid-involved overdose remains unclear. This study examined the neighborhood-level association between renter cost burden and fatal opioid-involved overdoses across time in an urban setting. We conducted a cross-sectional analysis of Chicago census tracts using locations of opioid-involved fatal overdoses from the Cook County Medical Examiner’s Office, 2015–2023 ( n = 8423). Renter cost burden, defined as the percentage of renter households spending ≥ 30% of income on housing, was obtained for Chicago census tracts from the American Community Survey. We used negative binomial regression to estimate the association between renter cost burden and severe cost burden (≥ 50%) and fatal overdose rate by year, controlling for neighborhood variables (e.g., income, segregation, and population density). We observed positive spatial autocorrelation, indicating spatial clustering of census tracts with a high proportion of cost-burdened renters and fatal overdose rates. We found consistent positive associations between fatal overdose rates and renter cost burden and severe cost burden over time, controlling for neighborhood demographics. For example, in 2023, each 10-percentage point higher proportion of cost-burdened renters was associated with a 9% higher fatal overdose rate (aIRR = 1.09, 95% CI [1.02, 1.17]). These findings support further investigation of the relationship between renter cost burden and fatal overdose and motivate studies using quasi-experimental designs to assess whether upstream housing interventions (e.g., rental assistance) may reduce fatal overdose risk.
- Open Access
- 19 August 2026
- Published by SAGE Publications in Substance use & addiction journal
Policy Pathways for Addressing Opioid-Stimulant Polysubstance Use
The United States continues to grapple with the shifting substance use landscape among the emerging concurrent use of opioids and stimulants. Polysubstance use (PSU) of opioids and stimulants, whether intentionally or unintentionally, has increased substance use related morbidity and mortality. Changes at the policy level are needed to effectively curb overdose and other adverse outcomes. This article outlines 3 policy changes that are particularly relevant to opioid-stimulant PSU: (1) reforms in opioid agonist treatment policy, (2) reforms in payment for evidence-based treatment, and (3) reforms of drug paraphernalia laws. The current overdose crisis requires a multidimensional paradigm shift toward patient-centered and harm reduction focused policies that will expand access to comprehensive evidence-based treatments and services for individuals engaged in opioid and stimulant PSU.
- 19 August 2026
- Published by SAGE Publications in Substance use & addiction journal
Open AccessPolicy Pathways for Addressing Opioid-Stimulant Polysubstance Use
The United States continues to grapple with the shifting substance use landscape among the emerging concurrent use of opioids and stimulants. Polysubstance use (PSU) of opioids and stimulants, whether intentionally or unintentionally, has increased substance use related morbidity and mortality. Changes at the policy level are needed to effectively curb overdose and other adverse outcomes. This article outlines 3 policy changes that are particularly relevant to opioid-stimulant PSU: (1) reforms in opioid agonist treatment policy, (2) reforms in payment for evidence-based treatment, and (3) reforms of drug paraphernalia laws. The current overdose crisis requires a multidimensional paradigm shift toward patient-centered and harm reduction focused policies that will expand access to comprehensive evidence-based treatments and services for individuals engaged in opioid and stimulant PSU.
A population‐based study exploring racial and gender inequities in polysubstance‐related deaths across the United States from 2004 to 2022
Background and aim: Recent studies have shown that Black men and women have been disproportionately impacted by overdose deaths within recent years, with their mortality rates rising sharply compared with their White counterparts. As the United States is in the fourth wave of the polysubstance use overdose crisis, it is unclear if polysubstance use is contributing to these disparate patterns of overdose mortality across race and gender. This study aimed to measure gender‐specific racial disparities in opioid related polysubstance use drug mortality in the United States from 2004 to 2022. Design, setting and participants: In this population‐level study of all deaths occurring in the United States, we obtained finalized death records of overdose fatalities identified using codes in the International Classification of Diseases , Tenth Revision (ICD‐10) from Centers for Disease Control (CDC) and Prevention's Wide‐Ranging Online Database for Epidemiologic Research (WONDER) Multiple Cause of Death file, from 2004 to 2022. Annual Percent Change (APC) and Annual Average Percent Change (AAPC) in age‐adjusted mortality rates (AAMR) for White men, White women, Black men, Black women, Hispanic men and Hispanic women were determined using joinpoint regression in this cross‐sectional study. Measurements: Joinpoint regression was used to examine mortality rates for opioid‐only, opioids with a stimulant, opioids with benzodiazepines, among racial/gender groups to measure temporal trends in age‐adjusted overdose mortality due to polysubstance‐related overdose. Findings: The final analytic sample included n = 627 793 opioid‐only deaths, n = 196 001 opioid‐stimulant and n = 117 322 opioid‐benzodiazepine overdose deaths. Opioid‐involved deaths increased across all groups, with the highest absolute rate change experienced by non‐Hispanic Black men (53.55 per 100 000, AAPC: 17.3%) and pronounced increases shown to occur between 2011 and 2022 (APC: 29.0%). Opioid‐stimulant polysubstance use deaths had the largest increases among non‐Hispanic Black men and women, with a 39.5% APC (2011–2022) for men and 36.2% APC (2012–2022) for women. Among Hispanic men, the rates accelerated 33.8% per year (2012–2022). For opioid‐benzodiazepine polysubstance use deaths, non‐Hispanic White men and women experienced the highest absolute rate change of 3.39 and 2.41 per 100 000, respectively. Conclusions: In the United States from 2004 to 2022, overdose deaths from polysubstance use escalated sharply across all racial and ethnic groups, with disproportionate increases across non‐Hispanic Black and Hispanic individuals, particularly in opioid‐stimulant and opioid‐only profiles.
A population‐based study exploring racial and gender inequities in polysubstance‐related deaths across the United States from 2004 to 2022
Background and aim: Recent studies have shown that Black men and women have been disproportionately impacted by overdose deaths within recent years, with their mortality rates rising sharply compared with their White counterparts. As the United States is in the fourth wave of the polysubstance use overdose crisis, it is unclear if polysubstance use is contributing to these disparate patterns of overdose mortality across race and gender. This study aimed to measure gender‐specific racial disparities in opioid related polysubstance use drug mortality in the United States from 2004 to 2022. Design, setting and participants: In this population‐level study of all deaths occurring in the United States, we obtained finalized death records of overdose fatalities identified using codes in the International Classification of Diseases , Tenth Revision (ICD‐10) from Centers for Disease Control (CDC) and Prevention's Wide‐Ranging Online Database for Epidemiologic Research (WONDER) Multiple Cause of Death file, from 2004 to 2022. Annual Percent Change (APC) and Annual Average Percent Change (AAPC) in age‐adjusted mortality rates (AAMR) for White men, White women, Black men, Black women, Hispanic men and Hispanic women were determined using joinpoint regression in this cross‐sectional study. Measurements: Joinpoint regression was used to examine mortality rates for opioid‐only, opioids with a stimulant, opioids with benzodiazepines, among racial/gender groups to measure temporal trends in age‐adjusted overdose mortality due to polysubstance‐related overdose. Findings: The final analytic sample included n = 627 793 opioid‐only deaths, n = 196 001 opioid‐stimulant and n = 117 322 opioid‐benzodiazepine overdose deaths. Opioid‐involved deaths increased across all groups, with the highest absolute rate change experienced by non‐Hispanic Black men (53.55 per 100 000, AAPC: 17.3%) and pronounced increases shown to occur between 2011 and 2022 (APC: 29.0%). Opioid‐stimulant polysubstance use deaths had the largest increases among non‐Hispanic Black men and women, with a 39.5% APC (2011–2022) for men and 36.2% APC (2012–2022) for women. Among Hispanic men, the rates accelerated 33.8% per year (2012–2022). For opioid‐benzodiazepine polysubstance use deaths, non‐Hispanic White men and women experienced the highest absolute rate change of 3.39 and 2.41 per 100 000, respectively. Conclusions: In the United States from 2004 to 2022, overdose deaths from polysubstance use escalated sharply across all racial and ethnic groups, with disproportionate increases across non‐Hispanic Black and Hispanic individuals, particularly in opioid‐stimulant and opioid‐only profiles.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Sage Open Medicine
- Vol. 11
A qualitative assessment of provider satisfaction and experiences with a COVID-19 community mobile health clinic outreach model in underserved Baltimore neighborhoods
Objective: Although previous studies have assessed provider perceptions about telehealth, no prior studies have qualitatively assessed the experiences and satisfaction of health-care providers with a community mobile health clinic model within underserved urban settings. Methods: This study draws on the views expressed by community health workers ( n = 4), registered nurses ( n = 2), Grace Medical Center outreach specialists ( n = 2), and physician assistants staffing LifeBridge Health’s virtual hospital ( n = 3) to understand their satisfaction and experiences with a COVID-19 community mobile health clinic in underserved Baltimore neighborhoods. Thematic analysis of the interviews was used to extract themes and subthemes of our health-care providers’ experiences with the community mobile health clinic model. Results: These individuals shared their experiences addressing social determinants of health, the perceived impact of community mobile health clinic, satisfaction with and limitations of the pilot project, as well as future implications for the community mobile health clinic model. Finally, ideas for how the model can fit into the existing healthcare delivery framework are suggested. Conclusion: The context surrounding the COVID-19 pandemic has provided a unique opportunity to critically address healthcare frameworks and models. The LifeBridge community mobile health clinic served as an initiative to truly bridge together community outreach and health access. Among the many themes, health-care providers on the team applauded the model for its potential to bring preventative health care to the patient with the goal of improving patient health outcomes.
- 1 January 2023
- Published by SAGE Publications in Sage Open Medicine
- Vol. 11
Open AccessA qualitative assessment of provider satisfaction and experiences with a COVID-19 community mobile health clinic outreach model in underserved Baltimore neighborhoods
Objective: Although previous studies have assessed provider perceptions about telehealth, no prior studies have qualitatively assessed the experiences and satisfaction of health-care providers with a community mobile health clinic model within underserved urban settings. Methods: This study draws on the views expressed by community health workers ( n = 4), registered nurses ( n = 2), Grace Medical Center outreach specialists ( n = 2), and physician assistants staffing LifeBridge Health’s virtual hospital ( n = 3) to understand their satisfaction and experiences with a COVID-19 community mobile health clinic in underserved Baltimore neighborhoods. Thematic analysis of the interviews was used to extract themes and subthemes of our health-care providers’ experiences with the community mobile health clinic model. Results: These individuals shared their experiences addressing social determinants of health, the perceived impact of community mobile health clinic, satisfaction with and limitations of the pilot project, as well as future implications for the community mobile health clinic model. Finally, ideas for how the model can fit into the existing healthcare delivery framework are suggested. Conclusion: The context surrounding the COVID-19 pandemic has provided a unique opportunity to critically address healthcare frameworks and models. The LifeBridge community mobile health clinic served as an initiative to truly bridge together community outreach and health access. Among the many themes, health-care providers on the team applauded the model for its potential to bring preventative health care to the patient with the goal of improving patient health outcomes.
- Open Access
- 19 March 2020
- Published by S. Karger AG in Public Health Genomics
- Vol. 23 (1-2) , 6-19
Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test
Introduction: Genetic risk modifier testing (GRMT), an emerging form of genetic testing based on common single nucleotide polymorphisms and polygenic risk scores, has the potential to refine estimates of BRCA1/2 mutation carriers’ breast cancer risks. However, for women to benefit from GRMT, effective approaches for communicating this novel risk information are needed. Objective: To evaluate patient preferences regarding risk communication materials for GRMT. Methods: We developed four separate presentations (panel of genes, icon array, verbal risk estimate, graphical risk estimate) of hypothetical GRMT results, each using varying risk communication strategies to convey different information elements including number of risk modifier variants present, variant prevalence among BRCA1/2 carriers, and implications and uncertainties of test results for cancer risk. Thirty BRCA1/2 carriers evaluated these materials (randomized to low, moderate, or high breast cancer risk versions). Qualitative and quantitative data were obtained through in-person interviews. Results: Across risk versions, participants preferred the presentation of the graphical risk estimate, often in combination with the verbal risk estimate. Interest in GRMT was high; 76.7% of participants wanted their own GRMT. Participants valued the potential for GRMT to clarify their cancer susceptibility and provide actionable information. Many (65.5%) anticipated that GRMT would make risk management decisions easier. Conclusions: Women with BRCA1/2 mutations could be highly receptive to GRMT, and the minimal amount of necessary information to be included in result risk communication materials includes graphical and verbal estimates of future cancer risk. Findings will inform clinical translation of GRMT in a manner consistent with patients’ preferences.
- 19 March 2020
- Published by S. Karger AG in Public Health Genomics
- Vol. 23 (1-2) , 6-19
Open AccessIllustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test
Introduction: Genetic risk modifier testing (GRMT), an emerging form of genetic testing based on common single nucleotide polymorphisms and polygenic risk scores, has the potential to refine estimates of BRCA1/2 mutation carriers’ breast cancer risks. However, for women to benefit from GRMT, effective approaches for communicating this novel risk information are needed. Objective: To evaluate patient preferences regarding risk communication materials for GRMT. Methods: We developed four separate presentations (panel of genes, icon array, verbal risk estimate, graphical risk estimate) of hypothetical GRMT results, each using varying risk communication strategies to convey different information elements including number of risk modifier variants present, variant prevalence among BRCA1/2 carriers, and implications and uncertainties of test results for cancer risk. Thirty BRCA1/2 carriers evaluated these materials (randomized to low, moderate, or high breast cancer risk versions). Qualitative and quantitative data were obtained through in-person interviews. Results: Across risk versions, participants preferred the presentation of the graphical risk estimate, often in combination with the verbal risk estimate. Interest in GRMT was high; 76.7% of participants wanted their own GRMT. Participants valued the potential for GRMT to clarify their cancer susceptibility and provide actionable information. Many (65.5%) anticipated that GRMT would make risk management decisions easier. Conclusions: Women with BRCA1/2 mutations could be highly receptive to GRMT, and the minimal amount of necessary information to be included in result risk communication materials includes graphical and verbal estimates of future cancer risk. Findings will inform clinical translation of GRMT in a manner consistent with patients’ preferences.